Short interest in Dianthus Therapeutics (DNTH, Financial) has increased notably, reaching a two-month high at 43% of free float. This rise comes amidst a recovery in the company's stock price. Despite the uptick in bearish sentiment, the days-to-cover ratio slightly decreased from 19.3 to 18.1. Over the past week, DNTH shares gained approximately 9%, adding to the stock's strong recovery of 59% since hitting a low on April 9. This positive momentum follows a significant downturn that saw the stock slump by 30% after missing earnings estimates in March.
Overall, the upward trajectory in the stock price of DNTH suggests a potential recovery, even as short interest mounts. Investors are closely watching these trends to assess future performance and market dynamics. With short interest continuing to climb, the market may witness heightened volatility, presenting both opportunities and risks for traders and investors involved with Dianthus Therapeutics.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Dianthus Therapeutics Inc (DNTH, Financial) is $49.11 with a high estimate of $58.00 and a low estimate of $36.00. The average target implies an upside of 126.63% from the current price of $21.67. More detailed estimate data can be found on the Dianthus Therapeutics Inc (DNTH) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Dianthus Therapeutics Inc's (DNTH, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
